Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation

被引：8
|
作者：
Jentzsch, Madlen [1 ]
Grimm, Juliane [1 ]
Bill, Marius [1 ]
Brauer, Dominic [1 ]
Backhaus, Donata [1 ]
Pointner, Rosmarie [1 ]
Goldmann, Karoline [1 ]
Schulz, Julia [1 ]
Niederwieser, Dietger [1 ]
Platzbecker, Uwe [1 ]
Schwind, Sebastian [1 ]
机构：
[1] Leipzig Univ Hosp, Med Clin & Policlin 1, Hematol & Cellular Therapy, Liebigstr 22,Haus 7, D-04103 Leipzig, Germany
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2021年 / 96卷 / 07期
关键词：
D O I：
10.1002/ajh.26179
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E237 / E239
页数：3
相关论文
共 50 条
  • [41] Clonal hematopoiesis-associated mutations as a marker of measurable residual disease (MRD) after allogeneic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML)
    Bischof, L.
    Ussmann, J.
    Brauer, D.
    Backhaus, D.
    Herrmann, L.
    Franke, G. -N.
    Vucinic, V.
    Metzeler, K. H.
    Platzbecker, U.
    Schwind, S.
    Jentzsch, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 238 - 238
  • [42] Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation
    Liang, Emily C.
    Chen, Connie
    Lu, Rong
    Mannis, Gabriel N.
    Muffly, Lori
    BONE MARROW TRANSPLANTATION, 2021, 56 (12) : 3091 - 3093
  • [43] Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation
    Emily C. Liang
    Connie Chen
    Rong Lu
    Gabriel N. Mannis
    Lori Muffly
    Bone Marrow Transplantation, 2021, 56 : 3091 - 3093
  • [44] Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation
    Josephine Lucero
    Muhned Alhumaid
    Igor Novitzky-Basso
    Jose-Mario Capo-Chichi
    Tracy Stockley
    Vikas Gupta
    Aniket Bankar
    Steven Chan
    Andre C. Schuh
    Mark Minden
    Jonas Mattsson
    Rajat Kumar
    Hassan Sibai
    Anne Tierens
    Dennis D. H. Kim
    Annals of Hematology, 2024, 103 : 1187 - 1196
  • [45] Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
    Eduardo Rodríguez-Arbolí
    Corentin Orvain
    Megan Othus
    Roland B. Walter
    Bone Marrow Transplantation, 2022, 57 : 1732 - 1734
  • [46] Significance of measurable residual disease in adults with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
    Rodriguez-Arboli, Eduardo
    Orvain, Corentin
    Othus, Megan
    Walter, Roland B.
    BONE MARROW TRANSPLANTATION, 2022, 57 (11) : 1732 - 1734
  • [47] HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation
    Roerden, Malte
    Nelde, Annika
    Heitmann, Jonas S.
    Klein, Reinhild
    Rammensee, Hans-Georg
    Bethge, Wolfgang A.
    Walz, Juliane S.
    CANCERS, 2020, 12 (07) : 1 - 10
  • [48] GATA2-Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation
    Sanchez-Petitto, Gabriela
    El Boghdadly, Zeinab
    Nicolet, Deedra
    Cooper, Julia
    Eisfeld, Ann-Kathrin
    Klein, Victoria
    Walker, Michael C.
    Mrozek, Krzysztof
    Bezerra, Evandro
    Brammer, Jonathan E.
    Denlinger, Nathan
    Shindiapina, Polina
    Penza, Sam
    Wall, Sarah A.
    Behbehani, Gregory K.
    Blachly, James S.
    Blaser, Bradley Wayne
    Borate, Uma
    Grieselhuber, Nicole R.
    Koenig, Kristin L.
    Larkin, Karilyn T.
    Long, Meixiao
    Mims, Alice
    Srisuwananukorn, Andrew
    Vasu, Sumithira
    de Lima, Marcos
    BLOOD, 2024, 144 : 7309 - 7310
  • [49] Outcome prediction by the knowledge bank approach in AML patients undergoing allogeneic stem cell transplantation
    Herrmann, L.
    Bischof, L.
    Backhaus, D.
    Brauer, D.
    Franke, G. -N.
    Vucinic, V.
    Platzbecker, U.
    Jentzsch, M.
    Schwind, S.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 108 - 108
  • [50] Monitoring Measurable Residual/Relapsing Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia
    Wethmar, K.
    Matern, S.
    Esseling, E.
    Bruggemann, M.
    Schliemann, C.
    Berdel, W. E.
    Lenz, G.
    Stelljes, M.
    ANNALS OF HEMATOLOGY, 2019, 98 : S57 - S57
12345